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Vector-borne diseases threaten the health of populations around the world.
While key interventions continue to provide protection from vectors, there
remains a need to develop and test new vector control tools. Cluster-
randomized trials, in which the intervention or control is randomly allocated
to clusters, are commonly selected for such evaluations, but their design must
carefully consider cluster size and cluster separation, as well as the movement
of people and vectors, to ensure sufficient statistical power and avoid contami-
nationof results. Islandsettingspresentanopportunity to conduct these studies.
Here,we explore the benefits and challenges of conducting intervention studies
on islands and introduce theBijagós archipelagoofGuinea-Bissau as a potential
study site for interventions intended to control vector-borne diseases.
This article is part of the theme issue ‘Novel control strategies for
mosquito-borne diseases’.1. Introduction
Vector-borne diseases (VBDs) contribute significantly to the global burden of
disease and remain a threat to over 80% of the world’s population [1,2]. The
pathogens responsible for these infections are transmitted by mosquitoes,
black flies, sand flies, ticks and other arthropods, the control of which is the
principal method available for controlling many VBDs.
Vector control aims to limit the transmission of pathogens by reducing or
eliminating human contact with the vector. The tools available for vector con-
trol include both chemical and non-chemical approaches that target either
larval or adult stages [3]. Insecticide-treated nets (ITNs) and indoor residual
spraying (IRS) have been the mainstay of malaria control [4]. However, recent
decades have witnessed the development of novel interventions that approach
the challenge of eliminating vector contact through the use of novel compounds
for existing interventions, mass drug administration (MDA) of ivermectin,
genetic modification and the introduction of bacteria that reduce or modify
the vector population [5–9].
The importance of developing new tools has been emphasized since 2017 as
evidence emerged that the global response to malaria had stalled. Malaria cases
were found to have increased in several countries [10], and this was coupled
with an increasing threat of Aedes-borne diseases. The global spread of dengue
and chikungunya viruses, as well as outbreaks of Zika virus disease and yellow
fever, clearly highlight the challenges faced with VBDs worldwide [11–13].
The World Health Organization’s Global Vector Control Response strategy
aims at strengthening vector control as a fundamental approach to preventing




2enhance vector control capacity and capability, and to
increase basic applied research and innovation [1]. Included
in these foundations is a requirement to improve the evidence
base of the impact of vector control interventions on infection
and human disease, which is generally weak beyond the core
interventions used for the control of malaria [14–16]. Rela-
tively few field studies have been performed with some
interventions, and these have often been poorly designed
and conducted [17]. As a consequence, their outcomes are
difficult to interpret and may give misleading results. There
remains an urgent need to understand the efficacy of current
interventions [18], and to measure the field suitability and
performance of new interventions.
Randomized controlled trials (RCTs) provide the least
biased and most robust estimate of an intervention’s efficacy
[19,20]. It is important to note that not all questions in vector
control can be answered with RCTs, and other study designs,
including observational studies, should be considered by
investigators [17,21]. For example, Kleinschmidt et al. [22]
used a prospective, observational cohort study design to inves-
tigate whether insecticide resistance was associated with a loss
of effectiveness of long-lasting insecticidal nets. Other study
designs may be more suitable where there is already strong
evidence that an intervention works; it would be unethical to
use a control arm that required study populations to use no
ITNs or IRS.
Where RCTs are appropriate and can be conducted well,
the allocation to treatment and control groups in a random
fashion is expected to provide no systematic differences
between groups that could be caused by confounding variables
[23]. Mosquito trials typically involve area-wide, rather than
individual, interventions, so their effects must be measured
at community, or cluster, level [24]. However, in order to be
able to provide evidence of efficacy, the study must carefully
consider cluster size and cluster separation. The movement of
people also needs to be considered, since it can contaminate
the study results, generally giving bias in the direction of the
null result [20].2. Benefits of using islands for cluster-
randomized trials
Avoidance of contamination is one of the primary reasons for
using a cluster randomization design for field trials. One of
the main strategies for reducing contamination is to choose
clusters for the trial that are well separated [23]. Rural commu-
nities, which are often selected for such studies [25,26], have the
benefit of being geographically dispersed, with less mixture of
populations expected than in urban areas. Natural barriers,
such as rivers or swamps, can also effectively increase the sep-
aration of clusters and prevent the mixture of populations.
An extension of this concept is to base intervention studies,
such as cluster-randomized trials (CRTs), on islands.
(a) Movement of human populations
Population movement is a major driver for infectious disease
transmission and is known to have a significant role in the
spatial spread of some diseases. The outbreak of Ebola in
West Africa from 2014 to 2016 is an important recent example
[27], but others include VBDs [28]. Dengue, transmitted by
Aedesmosquitoes, is recognized as the most rapidly spreadingmosquito-borne disease worldwide and is so intimately linked
with population movement that mobile phone-based mobility
estimates have been shown to predict the geographic spread
and timing of epidemics in some settings [29].
In addition to affecting disease transmission [30–32], the
movement of populations can impact disease control and elim-
ination strategies. First, where healthcare provision is based
around MDA, high population coverage is crucial to success
[33]. Elimination strategies, in particular, demand that high
levels of coverage are attained [34]. The movement of people
may mean that some individuals are missed, coverage targets
are not met, or there is re-introduction of disease [35].
Despite islands increasingly becoming part of global
systems of migration and flows of resources, the movement
of people to and from isolated islands is expected to be
moderate compared with movement in mainland settings
and, therefore, benefit the study of VBDs and other infectious
diseases. Where studies are being conducted to assess the effi-
cacy of an intervention, such as through CRTs, the movement
of individuals between clusters could lead to dilution of the
intervention’s effects. Careful study design is needed to coun-
ter these issues [17]. In the case of mobile interventions such
as insecticide-treated clothing or MDA of an endectocide, a
type of systemic insecticide that has activity against both
endo-parasites and ecto-parasites, substantial movement of
treated individuals into control-group clusters could result
in a reduction in the local mosquito population and an under-
estimate of the impact of the intervention. Conversely, in the
trial of a repellent, those wearing repellents may divert mos-
quitoes to unprotected individuals [36] and in this situation
inflate the apparent effect of the intervention. By conducting
intervention studies on islands, these effects may be
minimized.(b) Movement of vector populations
Themovement ofvectorpopulations is a further complication for
intervention studies and is another motive for the use of islands.
The dispersal range of Anopheles gambiae mosquitoes has been
estimated through mark–release–recapture experiments to be
less than 7 km, and more commonly in the range of 0.5–1 km
[37–39]. Thismeans that, if intervention clusters are considerably
closer together, there is more opportunity for contamination.
Experiments in which labelled An. gambiae were released from
a Gambian village have shown that, while the majority of re-
caught mosquitoes remained in the same village, there was
also the movement of mosquitoes to neighbouring villages situ-
ated 1–1.4 km away. This suggested that movement could
seriously affect the entomological evaluation of vector control
programmes, such as studies with ITNs, in areas where treated
and untreated villages were interspersed [40].
The restriction of movement of mosquito populations is
particularly important for studies with genetically modified
mosquitoes. The concern here is not just with assessing the
impact of the intervention, which might be to use transgenes
to suppress a local mosquito population or replace it with a
population that is refractory to the development of pathogens
[41,42], but one of mitigating risks. Geneticallymodified strains
are designed to be competitive against wild populations, and
it would be difficult to halt the spread of transgenes from a
self-propagating, genetically modified mosquito population if
some unanticipated negative side effects were identified follow-




3field trials of genetically modified mosquitoes be carried out
with individuals that are genetically sterile, and that the release
site is geographically isolated, so that there is a negligible risk
of spread of mosquitoes from any accidental release [43,44].
Oceanic or lacustrine islands are natural choices for such field
sites and have been considered as release sites that would
allow the success and risks associatedwith geneticmodification
of An. gambiae to be assessed.
Isolated riverine islands were selected for a field trial
aimed at the suppression of insular Aedes albopictus popu-
lations through releases of irradiated male mosquitoes that
also carried a transinfected Wolbachia strain incompatible
with local females [45]. Several million factory-reared adult
males were released in residential areas of islands in Nansha
and Panyu Districts in Guangzhou, the city with the highest
dengue transmission rate in China, and resulted in near elim-
ination of field populations [45]. Before release, themosquitoes
were irradiated with an X-ray dose known to effectively steri-
lize females but to not negatively affect male competitiveness.
Wolbachia is maternally inherited; accidental release of fertile
females may, therefore, result in the unintended invasion of
the novel Wolbachia strain in the local population and would
render any future male releases carrying the strain ineffectual.
The Nansha and Panyu District islands are relatively isolated.
Although there is evidence of passive mosquito dispersal
along with human transportation networks, nearby islands
provided control sites for means of comparison [45]. Here,
as elsewhere [46,47], islands have allowed for the precise
monitoring of vector population suppression with limited
interference from outside populations.
Rusinga Island in Lake Victoria, western Kenya, provides
another example of the use of islands for the evaluation of
vector control interventions. The island was used in a stepped
wedge CRT to investigate the use of mass mosquito trapping
for malaria control [48]. The island is connected to the main-
land via a causeway, which is used for transport to the larger
town of Mbita, where there is one of the two medical clinics
that serve Rusinga Island. The island is a contained area, and,
therefore, considered ideal for the use of a stepped wedge
trial design. However, the island’s proximity to the mainland,
and its dependency on mainland infrastructure, may result in
contamination from mainland vector populations. There are
more remote islands in Lake Victoria, including Mageta,
Magare and Ngodhe islands, which may be less likely to
experience vector movements from the mainland [49].3. Challenges of island cluster-randomized trials
While there are clear benefits of working on islands, such
environments also present challenges to intervention studies.
Island groups in remote settings have obvious logistical limit-
ations, making it difficult for study teams and equipment to
travel to and between study locations, and this can add study
costs, which are often considerable for CRTs.
(a) Study clustering
To adequately establish the effect of intervention through
CRTs, it is crucial to ensure adequate numbers of clusters to
satisfy the study design. However, the number of islands in
an archipelago may restrict options for clustering, and
indeed, where a study requires a certain number of individ-
uals, the population sizes on some islands be a limiting factor.Sample size estimates must consider the possibility of
within-cluster correlation as a result of between-cluster varia-
bility. For example, the availability of breeding sites for
vectors, or differences in access to healthcare, may mean that
there are differences in rates of infectious disease between clus-
ters [23]. To ensure that study outcomes can be accurately
observed, any heterogeneity between clusters must be taken
into account when designing CRTs. Where there is a high
degree of correlation in the outcome, whereby some clusters
report low levels of disease prevalence and others much
higher, it is more difficult to demonstrate an intervention
effect without a very large number of clusters [21]. Studies of
malaria prevalence suggest that for CRTs it may be necessary
to assume high between-cluster variability when estimating
realistic sample sizes [50].(b) Translation of results to other settings
A further consideration for conducting research studies in an
island setting is the ability to translate findings to other set-
tings. The question of external validity asks whether the
results obtained in a trial may be generalized to other settings,
whichmay differ from the study settingwith respect to charac-
teristics that influence the outcome, and whether the results
have been affected by particular geographical, temporal,
socio-economic and ethnical factors that may not be present
at other study sites [51]. Island populations may have different
cultures and traditions, and can even differ genetically from
those in other areas owing to genetic drift or differences in
ancestral populations, potentially resulting in an effect modifi-
cation [52,53]. It is conceivable that an intervention involving
an island population would have different outcomes when
implemented elsewhere. This holds for both human and
vector populations. For instance, a glycine–serine mutation
in the acetylcholinesterase (ace) gene that confers high levels
of resistance to carbamates and organophosphates was not
found to be present in An. gambiae from Bioko Island, 30
miles off the coast of Cameroon where bendiocarb resistance
has been documented [54]. This indicates that there is little
gene flow between Bioko Island and the nearest mainland
populations. Insecticide treatments that are effective in con-
trolling mosquito populations on Bioko might have limited
effect in other areas. It is, therefore, important that the results
of any efficacy studies are considered in the context of their
settings. For these reasons, the World Health Organization
Vector Control Advisory Group requires data from at least
two well-conducted RCTs in different and complementary
entomological settings, ideally covering two transmission sea-
sons, to accept new first-in-class products for vector control
[55]. While this can help ensure that products reaching
the marketplace have public health value in more than one
setting, it requires the use of more than one island group for
intervention studies.
Islands were selected for the first interventions using RIDL
(Release of Insects carrying a Dominant Lethal gene) mosqui-
toes. Approximately 3.3 million engineered male Aedes aegypti
were released in a 23-week period in 2010 in a field site on
Grand Cayman, an island in the Caribbean. Monitoring of ovi-
traps at the release sites and a control site indicated strong
population suppression in the treated area during the last
seven weeks of the release period [46]. This positive outcome
and successful demonstration of population suppression pro-
vided encouragement for RIDL mosquitoes and genetic
Figure 1. Bijagós archipelago, situated off the Atlantic coast of Guinea-Bissau. Inset shows position of Guinea-Bissau on the coast of West Africa. Adapted from





control strategies in general for population suppression. The
island study was followed by sustained field releases in a
suburb of Juazeiro, Bahia, Brazil. While reductions seen in ovi-
trap indices, compared with the adjacent no-release control
area, were similar to those estimated in the Cayman trials
[56], results from a large-scale release in Piracicaba have not
been published in academic journals. Challenges in producing
sufficient numbers of transgenic mosquitoes can limit the
number released per hectare [46] and thus make it difficult
to replicate successes in larger areas.
The control of arboviral diseases through the use of
Wolbachia also requires the mass-rearing and release of mos-
quitoes. Wolbachia can reduce mosquito competence for a
variety of RNA viruses, including dengue and chikungunya
[57]. Many Wolbachia strains induce a sperm–egg inviability
known as cytoplasmic incompatibility (CI) that provides
female carriers with relative reproductive advantage, allowing
the Wolbachia strain to invade naive insect populations [58].
The reproductive advantage conferred by CI increases with
Wolbachia population frequency, although Wolbachia infection
is also often accompanied by deleterious effects on some life-
history traits. This combination of frequency-dependent
fitness advantages and frequency-independent costs results
in an invasion threshold—below the threshold the Wolbachia
strain will tend to be lost from a population, but if the
threshold is surpassed, the Wolbachia strain will tend to
spread. It is, therefore, important that mosquito releases are
sufficient to exceed the threshold frequency. In the case of
the wMel Wolbachia infection in Ae. aegypti, it is estimated
that the frequency of wMel must reach 20–30% in the
population for successful invasion [59]. The rate at which
Wolbachia spreads through a population depends on the
distance mosquitoes disperse and the cost of Wolbachia
infection, which are likely to be affected by environmental con-
ditions [60]. Indeed, different rates of spreading have beenobserved at different release sites in Cairns, Australia [61].
Importantly, the ability of Wolbachia to become established
can be affected by the isolation of the population. If an Aedes
population is not isolated, a relatively small population of
infectedmosquitoes can be swamped by immigrants from sur-
rounding Wolbachia-free populations, and the influx is
expected to push the prevalence of Wolbachia below the inva-
sion threshold [60]. There is, therefore, the assumption that
an intervention will perform differently on an island from in
a mainland setting, and theoretical models have been devel-
oped to guide programmes that deploy Wolbachia for the
purposes of vector control [59].4. The Bijagós archipelago
A unique setting for investigations of infectious disease epid-
emiology and the efficacy of control interventions is offered by
the Bijagós archipelago of West Africa. The archipelago, made
up of 88 islands, is situated within an area of approximately
13 000 km2 in the Atlantic Ocean, off the coast of Guinea-
Bissau (figure 1). Collectively, the islands cover 900 km2,
with the farthest being less than 100 km from the mainland.
Eighteen of the islands are permanently inhabited, with an
estimated population of around 24 000 people. Many of the
others are reserved for seasonal agricultural use. The islands
host a diversity of ecosystems from mangroves to forests, and
provide habitats for a range of arthropod vectors of disease.
(a) Vector-borne diseases and current interventions on
the Bijagós archipelago
The Bijagós archipelago is endemic for Plasmodium falciparum
malaria and records the highest prevalence (more than 30
confirmed cases per 100 population) in Guinea-Bissau [62].
royalsocietypublishing.org
5Standard malaria control interventions implemented on the
Bijagós archipelago by the National Malaria Control
Programme include ITNs, intermittent preventive treatment in
pregnancy, and case diagnosis and treatment with artemisinin-
based combination therapy (artemether–lumefantrine). There
are no current plans for scale-up of additional malaria control
measures on the islands, so there is an excellent opportunity to
conduct interventional studies to reduce malaria transmission
in these communities using novel cost-effective approaches./journal/rstb
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376:20190807(b) Previous studies on the Bijagós archipelago
Previous studies of the archipelago have monitored human
activity and surveyed mosquito populations [63,64]. Using
indoor adult light traps and larval dipping at potential
breeding sites, our group characterized vectors likely to be
responsible for the majority of malaria transmission. The
island of Bubaque was found to maintain both wet- and
dry-season An. gambiae s.l. populations, with An. gambiae s.s.
being the primary wet season vector, and the salt water-
tolerant species Anopheles melas likely to be responsible for
the majority of dry-season transmission [64]. Anopheles melas
is relatively rare [65], but can breed year-round in the island’s
abundant littoral habitats and mangrove swamps, and thus,
as in other coastal areas [66,67], maintain a relatively constant
dry-season population. By contrast, An. gambiae s.s. and
Anopheles coluzzii populations on Bubaque decline as the fresh-
water habitats that support their breeding become scarce [64].
The entomological surveys on the archipelago report that
An. gambiae s.s. and An. coluzzii reside in sympatry and exist
as hybrid forms [64,68]. These hybrids are found at much
higher frequencies than are observed elsewhere in Africa
[69]. A moderate degree of resistance to α-cypermethrin,
but full susceptibility to permethrin, has been recorded.
Both kdr and metabolic resistance mechanisms were detected,
which could compromise current control methods that rely
on insecticide-treated bed nets [64].
The movement of people within and between a subset of
the Bijagós islands was the subject of a study by Durrans et al.
[63], which showed that, although there was likely less
migration than on the mainland owing to their geographical
remoteness, the movement was a common feature of island
life for men and women alike. While this was a relatively
small study, it showed that typical reasons for travel included
subsistence activities, family events, income-generating
activities, cultural festivities and healthcare. These move-
ments often occurred erratically all-year-round, with the
exception of seasonal travel within and between islands for
agricultural purposes. Understanding the patterns of move-
ment is important for tailoring and increasing the reach of
public health interventions, and this analysis of the Bijogo
population will facilitate future studies on the islands. Tem-
poral movement and migration within the island
communities can be mapped and monitored during trials,
but there are also opportunities to measure epidemiological
outcomes through active detection of disease cases in sentinel
cohort populations, as has been used for vector control studies
in other settings [70,71].
Marsden et al. [65] evaluated the suitability of the Bijagós
archipelago as a potential field site for the release of geneti-
cally modified An. gambiae. Given the broad geographical
distribution of An. gambiae species, there are surprisingly
few islands where these mosquitoes are active in malariatransmission and where there is a sufficient geographical dis-
tance between clusters to ensure isolation. The study
collected mosquitoes from a single site on three of the 88
islands, analysing 208 mosquitoes, in comparison with 998
mosquitoes collected and analysed from the Comoro Islands.
However, despite the distance of the Bijagós islands from
mainland Guinea-Bissau, there was no evidence of genetic
sub-division between island and mainland sites, which
suggests that there is some degree of ‘island hopping’ on
the archipelago. As a result of this evidence, the authors con-
cluded that the Bijagós archipelago was not sufficiently
isolated for the release of transgenic strains and found the
island of Grande Comore in the Indian Ocean to be a more
suitable site for trials with genetically modified strains [65].
Further, the presence of both An. coluzzii and An. gambiae
s.s. on the Bijagós islands, and evidence of hybridization
between them [68], would complicate the implementation
of an isolated genetically modified mosquito trial on the
archipelago.
A feature that was not relevant to the release of engin-
eered mosquitoes, but is highly beneficial for other studies,
is the presence of more than one island. The Comoro archipe-
lago constitutes just four islands, while the Bijagós
archipelago counts 18 inhabited islands, opening consider-
able opportunities for clustering of intervention and control
arms in a CRT.
(c) Future vector control studies on the Bijagós
archipelago
The Bijagós archipelago offers a setting for the evaluation of
other vector control tools. However, it remains important to
take potential contamination between clusters into consider-
ation. If different islands of the archipelago were to serve as
different clusters, mosquitoes originating on a control-group
island that disperse to a treatment island, either through
the inadvertent movement of mosquitoes with local boat traf-
fic or by wind-assisted flight, could, as with human
population movement, interfere with the interpretation of
the impact of the intervention. Such impacts are expected to
be smaller in island settings than in areas without such phys-
ical barriers, but they can be anticipated and minimized
through study design.
To help minimize contamination, buffer zones can be
designated within clusters. If buffer zones are used, each
island is split into an inner core area and an outer buffer
zone. The intervention is delivered to the whole island, but
measurements are only taken in the core area. The advantage
is that contamination can be reduced because it is more likely
to occur in the buffer zone where no measurements are
taken. A balance must be struck when deciding on the size
of the buffer: the bigger the buffer the less contamination
will occur in the core area, but the core area must be big
enough to ensure a sufficiently large sample can be taken
to maintain statistical power. The use of buffer zones, and
their size, should consider the average distance travelled by
mosquitoes and the amount of migration of local human
populations. Such zones were used in the first randomized
trial to provide evidence that IRS, when used in combination
with ITNs, can give significant added protection against
malarial infection compared with ITN use alone [72].
It is essential that any randomized trial is sufficiently
powered to detect a meaningful difference between the two
(a) (b) (c)







Figure 2. Cluster selection and the use of buffer zones. Hypothetical buffer zones of 2.5 km radius (shown as blue discs) around villages (shown as blue dots)
potentially allow for the establishment of multiple clusters on a single island (a). Buffer zones of 5 km radius, requiring villages to be at least 10 km apart, would
prevent nearby villages from being in different intervention clusters (b). As a result, some villages (shown in orange) could be excluded from the study (c). Adapted





arms. For a CRT, the principal factors that determine power
are: the number of clusters, the number of individuals
measured in each cluster, the underlying prevalence/inci-
dence of the endpoint, the difference between the two arms
in the endpoint, and the variation between the clusters in
the endpoint. A previous CRT that investigated the effect of
ivermectin MDA on malaria only had eight clusters and
was probably very underpowered [73]. A less appreciated
consequence of using too few clusters is that some statistical
models commonly used for the analysis of CRTs will not per-
form well and may lead to increased type 1 errors [73]. The
Bijagós archipelago’s 18 available inhabited islands would
allow a medium-sized, two-armed, CRT to take place there
and the sample size should be sufficient for many disease
outcomes. For example, for a trial of the use of ivermectin
on the archipelago, using data collected from previous
studies, we estimate there will be over 90% power to detect
a difference of 5 versus 10% malaria prevalence in the
intervention and control arms, respectively.
Stratified randomization is often used in CRTs to increase
power [23]. Clusters that are similar in some way are grouped
into strata. Analysis is carried out within strata, and the simi-
larity of clusters within each stratum reduces between-cluster
variation and, hence, increases power. Care must be taken
when deciding which variable(s) are used for stratification. If
clusters are stratified on the basis of variables that are not
associated with the study endpoint, then power may in fact
be reduced. Which variables are strong predictors of endpoints
will be specific to the disease in question; for VBDs, ecological
variables related to the mosquito’s life cycle may be appropri-
ate. A common stratification variable that is appropriate in a
wide variety of circumstances is a cluster-level baseline
measure of disease prevalence of incidence.
In the Bijagós archipelago, should more than 18 clusters,
representing the number of inhabited islands, be needed in
a CRT, islands must be split wherever possible following
the above considerations. For example, the island of Caravela
has a population numbering more than 4200 people. There
are population centres on the north, south and western
parts of the island, separated by at least 5 km of sea or
land. The island could be split into two or more clusters.
The clusters on an island could form a stratum for randomiz-
ation, with one population centre being selected, at random,
for assignment to the treatment arm and the other assigned to
the control arm. This would allow for more clusters to be
created beyond the natural limit of 18, but clearly each
would have a smaller population size. The choice of buffer
zone size might also have an impact on the power of thestudy. Large buffer zones will reduce the possibility of popu-
lation mixing, but might demand that some sites are excluded
from the study altogether (figure 2).
A cluster-randomized control trial investigating the use
of adjunctive ivermectin MDA to control malaria will be
conducted in the Bijagós islands. Through interruption of
transmission of malaria by reducing the human reservoir
of P. falciparum and vector survival, dihydroartemisinin–
piperaquine and adjunctive ivermectin MDA is expected to
reduce the prevalence of the disease. Ivermectin has trans-
formed the treatment of parasitic diseases, having been
used effectively in MDA campaigns against onchocerciasis
and lymphatic filariasis (LF) [74,75]. The drug has also been
administered for head lice [76] and has had effects on scabies
and intestinal helminths [77,78]. Ivermectin MDA for malaria
controlwouldprovide an opportunity for collaboration between
various disease control programmes, such as the Global Pro-
gramme to Eliminate Lymphatic Filariasis (GPELF) and the
Onchocerciasis Elimination Program of the Americas (OEPA).
Ivermectin is an attractive option for the control of
malaria, as it kills mosquitoes that feed on individuals who
have been administered an appropriate dose, and so targets
mosquitoes regardless of whether they feed indoors or out-
doors, during the day or at night [79]. Therefore, it can be
used as a tool to complement ITNs and IRS. Sub-lethal effects
of ivermectin on mosquitoes include reductions in fecundity
and egg hatch rate [80,81], and it has also been shown to
have a sporontocidal effect against Plasmodium vivax in host
Anopheles [82]. This means that there can be community-
wide effects of MDA campaigns, and modelling predictions
suggest that ivermectin could be a valuable addition to
malaria control in areas with seasonally persistent high
malaria transmission, where existing interventions have
failed to provide sufficient protection, or in areas that are
approaching elimination [83].
The Bijagós archipelago has been targeted for an ivermectin
campaign owing to its highly seasonal and stable malaria
transmission. It also is co-endemic for malaria and neglected
tropical diseases such as LF, soil-transmitted helminths and
scabies. The control and elimination of these diseases has
been prioritized by the Guinea Bissau Ministry of Public
Health. Previous trachoma research on the islands has shown
that MDA can be an effective and feasible strategy to eliminate
infectious diseases in these communities [84]. MDA studies
implemented to assess the efficacy of ivermectin for malaria
control should employ both clinical and entomological
primary outcomes [70]. Assessors should be blinded to the
intervention received by participants to reduce detection
royalsocietypublishing.org/journal/rstb
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7biases, and entomological data should be collected through
standardized methods, such as indoor traps for mosquito
counts and an ovarian tracheation technique for determining
mosquito age through parity [85,86]. Given that reductions in
malaria prevalence may not necessarily correspond to
reductions in clinical incidence [87], clinical outcomes should
ideally include bothmeasures of prevalence in the study popu-
lation and measures of clinical incidence, determined through
active case detection in cohorts.
The proposed ivermectin trial potentially places restrictions
on the further use of the Bijagós archipelago for intervention
studies. The number of islands, and size of their populations,
only allow for a single trial of this type to be conducted at
any one time. It may be expected that the ‘treated’ clusters
would have considerably different epidemics to take into con-
sideration for follow-on trials, and it would be necessary to
treat the ‘control’ clusters before subsequent trials can begin.
It would also be necessary to allow a suitable period of time
to pass before these clusters reach equivalence. B
376:201908075. Conclusion
The evaluation of vector control tools requires well-designed
studies that generate evidence of efficacy while minimizingpotential biases. Although islands can have limitations,
including restrictions on eligible populations and geography,
they have unique features that align them well with CRT with
novel vector control tools. The Bijagós islands are endemic for
a range of vector-borne and neglected tropical diseases and
have already been the subject of entomological and demo-
graphic studies that will facilitate future intervention and
surveillance studies on the islands.
Caution should be taken in regarding islands as small-
scale models of the wider world, but it is also important to
avoid the danger of exceptionalism, regarding islands as
being unique [88]. Many of the interventions that are cur-
rently in use or are in development could benefit from
studies of efficacy and suitability, and conducting such
trials on the Bijagós archipelago or other island groups will
demonstrate their field suitability and potential value to
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